Trevena’s Heart Failure Candidate Flops in Phase 2b

Trevena’s investigational drug TRV027 stumbled in a Phase 2b trial, missing its primary and secondary endpoints, leading the company to focus on other studies.

The pivotal trial assessed TRV027 as a treatment option for patients with acute heart failure, comparing the candidate coupled with standard therapy to placebo plus standard therapy.

The goal of the study was to examine TRV027’s effects on mortality, worsening heart failure, hospital readmission rate, dyspnea and length of hospital stay, the company said.